The Value of Diagnostic Pre-Launch Planning for Targeted Therapies – Through the PD-L1 Lens | Diaceutics

The Value of Diagnostic Pre-Launch Planning for Targeted Therapies – Through the PD-L1 Lens

May 10th, 2016

Peter Keeling
Sanna Jousi


Are you planning to launch a diagnostic alongside a targeted therapy in the next 18-24 months. This webinar highlights Diaceutics’ recent PD-L1 lost therapy opportunity assessment, which demonstrated that every $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost. It also highlights how effective diagnostic planning can maximize your therapy revenue opportunity.

Listen to this webinar to learn:

  • that $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost; and
  • why ineffective diagnostic launch planning can lead to lost therapy revenue and how, with the proper planning tools, the maximum therapy opportunity can be achieved.

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications